NCT02703272 2022-12-02A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin LymphomaJanssen Research & Development, LLCPhase 3 Terminated72 enrolled 36 charts